On April 10, 2025, the US FDA announced that it has a long-term plan to eliminate conventional animal testing in drug development, starting with monoclonal antibodies (mAbs).1 Instead, within 3-5 years, the expectation will be to leverage an integrated safety assessment approach, combining information from a comprehensive battery of New Approach Methodologies (NAM). These methodologies…